10-Q: Accuray Reports Q2 Fiscal Year 2025 Results: Revenue Up, Navigating Economic Headwinds

Accuray Incorporated reports increased revenue for Q2 FY25, but continues to face challenges from macroeconomic factors and supply chain issues.

Summary

• Accuray Incorporated's Q2 FY25 report shows an increase in total net revenue to $116.174 million, compared to $107.238 million in Q2 FY24.
• Product revenue increased by 19% to $61.189 million, while service revenue decreased slightly by 1% to $54.985 million.
• The company's gross profit increased to $41.892 million, representing 36.1% of net revenue.
• Accuray reported net income of $2.537 million, a significant improvement from the net loss of $9.621 million in the same quarter last year.
• The company is navigating challenges related to inflation, supply chain disruptions, and foreign currency exchange rate fluctuations.
• Accuray's order backlog at the end of the period was $463.056 million.
• The company believes it has sufficient cash resources to fund operations for at least the next 12 months.
• A material weakness in internal control over financial reporting related to manual journal entries was remediated during the quarter.
• The company is working to remediate a remaining material weakness related to inventory cycle counts.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While revenue and income have improved, the company faces significant economic headwinds and internal control challenges.

Positives

• Increased product revenue indicates strong demand for Accuray's systems.
• Return to net income suggests improved operational efficiency.
• Remediation of a material weakness in internal control over financial reporting strengthens financial processes.
• Strong order backlog provides a foundation for future revenue.
• Net revenue increased $8.9 million and $6.6 million during the three and six months ended December 31, 2024, respectively, as compared to the same periods in the prior fiscal year, primarily due to a by a higher volume of shipments to China, the APAC region and Japan.

Negatives

• Service revenue decreased slightly by 1% in Q2 FY25.
• The company faces ongoing challenges from macroeconomic conditions, supply chain issues, and foreign currency fluctuations.
• A material weakness related to inventory cycle counts remains unaddressed.
• Revenues from the Americas region are being negatively impacted by reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines which we expect will continue to have an impact on net revenue through fiscal year 2026.

Risks

• Macroeconomic conditions, including inflation and supply chain disruptions, could continue to negatively impact gross margins and net income.
• Failure to comply with debt covenants could limit the company's ability to finance future operations.
• Intense competition and rapid technological change in the industry could render Accuray's products obsolete.
• Product liability claims or recalls could be expensive and harm the company's reputation.
• Disruptions to information technology systems or cyberattacks could compromise sensitive data and disrupt operations.
• Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted net revenue since fiscal year 2024, and we expect this will continue to have an impact through fiscal year 2026.

Future Outlook

Accuray expects macroeconomic challenges and supply chain issues to persist through fiscal year 2025, impacting gross margins and net income. Reduced budgets and lower capital deployment priority for radiotherapy equipment, along with longer customer installation timelines, in the United States have negatively impacted net revenue since fiscal year 2024, and we expect this will continue to have an impact through fiscal year 2026.

Management Comments

• Management is carefully evaluating the company's liquidity position and monitoring the actions of customers and suppliers.
• Management is reviewing near-term financial performance as the uncertainty related to macroeconomic factors continues to unfold.
• Based on cash and cash equivalents balance, available debt facilities, current business plan and revenue prospects, management believes the company will have sufficient cash resources and anticipated cash flows to fund operations for at least the next 12 months.

Industry Context

The medical device industry, particularly the noninvasive cancer treatment field, is subject to intense competition and rapid technological change. Accuray competes with established players like Varian and Elekta, as well as emerging companies. The company's success depends on its ability to innovate and demonstrate the advantages of its products over competing technologies.

Comparison to Industry Standards

• Accuray's main competitors in the radiation therapy market are Varian Medical Systems, Inc., a Siemens Healthineers company (Varian), Elekta AB (Elekta), RefleXion Medical Inc. and Zap Surgical Systems.
• Varian has been the leader in the external beam radiation therapy market for many years and has the majority market share for radiation therapy systems worldwide.
• The report does not provide enough information to compare Accuray's financial performance to specific industry benchmarks or competitors' results.

Management Changes

Legal Proceedings

• From time to time, the Company is involved in legal proceedings, including claims, investigations, and inquiries, arising in the ordinary course of its business.
• Currently, management believes the Company does not have any probable and reasonably estimable material losses related to any current legal proceedings and claims.

Related Party Transactions

• Includes accounts receivable from the joint venture, an equity method investment, of $ 26,082 and $ 25,339 at December 31, 2024, and June 30, 2024 , respectively.
• Includes other receivables from the joint venture, an equity method investment, of $ 377 and $ 743 at December 31, 2024, and June 30, 2024 , respectively.
• Includes sales of products to the joint venture, an equity method investment, of $29,722 and $58,366 during the three and six months ended December 31, 2024 and $17,890 and $39,842 during the three and six months ended December 31, 2023, respectively.
• Includes sales of services to the joint venture, an equity method investment, of $5,179 and $9,237 during the three and six months ended December 31, 2024 and $4,134 and $6,988 during the three and six months ended December 31, 2023, respectively.
• Includes cost of revenue from sales to the joint venture, an equity method investment , of $ 15,001 and $ 35,892 during the three and six months ended December 31, 2024 and $ 11,102 and $ 26,373 during the three and six months ended December 31, 2023, respectively.
• Includes charge backs to the joint venture, an equity method investment, related to research and development of $ 377 and $ 732 during the three and six months ended December 31, 2024, and $ 67 and $ 199 during the three and six months ended December 31, 2023 , respectively.
• Deferred intra-entity gross profit recognized on sales to the JV $ 11,745 $ 4,728 $ 14,459 $ 6,313
• Deferred intra-entity gross profit on sales to the JV ( 7,232 ) ( 2,858 ) ( 13,565 ) ( 6,019 )
• Net recognized gross profit on sales to the JV (1) $ 4,513 $ 1,870 $ 894 $ 294

Stakeholder Impact

• Shareholders: The report provides information on the company's financial performance and future outlook, which can influence investment decisions.
• Employees: Changes in management and potential cost-saving initiatives may impact employee morale and job security.
• Customers: The company's ability to navigate supply chain challenges and maintain product quality is crucial for customer satisfaction.
• Creditors: Compliance with debt covenants and the company's liquidity position are important for creditors.
• Suppliers: The company's reliance on single-source suppliers and its ability to manage supply chain disruptions can impact supplier relationships.

Next Steps

• The company will continue to monitor its recorded goodwill for indicators of impairment every fiscal quarter.
• The Company plans to adopt ASU 2023-09 on July 1, 2025.
• Management is committed to addressing and remediating the remaining cycle count material weakness described above and has developed a plan to enhance the design and operating effectiveness of our internal controls over financial reporting.

Key Dates